ASHPOfficial

This podcast reviews the newly revised ASHP Guidelines on Emergency Medicine Pharmacist Services.  Originally released in 2011, a group of emergency medicine clinical pharmacy specialist content experts conducted a literature search for updated supporting evidence and updated the recommendations to establish reasonable goals on attainable best practices.

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In this presentation from the 2020 Midyear Clinical Meeting, content matter experts describe clinical trial designs for COVID-19 vaccine candidates, identify important documentation requirements and safety surveillance measures and actions, outline opportunities to address vaccine hesitancy, calculate the number needed to vaccinate to stop widespread community transmission of SARS CoV-2 and discuss clinical implications related to COVID-19 vaccine(s) made available through Emergency Use Authorization. 

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

MCM COVID-19 Presentation: Roadmap to a COVID-19 Vaccine: Clinical Considerations for Ensuring Safety and Efficacy Part 1Vaccine Clinical Trial Design and Vaccine Development During a Pandemic

In this presentation from the 2020 Midyear Clinical Meeting, content matter experts describe clinical trial designs for COVID-19 vaccine candidates, identify important documentation requirements and safety surveillance measures and actions, outline opportunities to address vaccine hesitancy, calculate the number needed to vaccinate to stop widespread community transmission of SARS CoV-2 and discuss clinical implications related to COVID-19 vaccine(s) made available through Emergency Use Authorization.

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In today's episode, we take listeners on a deeper dive of specific details of FDA Emergency Use Authorizations: what they are, what they are not, how they are determined, specific nuances that they may subsequently enact, and how they are determined for approval. The topic is intended to be general around EUA’s, but COVID-19 specific examples are highlighted as well as those that have brought public attention to the EUA process. 

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This two-part podcast series provides listeners with a review of updates to the diabetes treatment guidelines.  Speakers share an overview of guideline updates, evaluate treatment options, and discuss methods of addressing issues related to affordability and access to medications.   

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In this interprofessional conversation, expert faculty discuss the clinical effects of neuromuscular blocking and reversal agents, including key components of NMB and reversal strategies during the intraoperative phase of care and neuromuscular monitoring. Patient risk factors and mitigation of post-operative complications will also be discussed.

To learn more about neuromuscular blockade and reversal visit www.ashpadvantage.com/nmbreversal/

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

February 7-14 is the Congenital Heart Defects (CHD) Awareness Week.  Join members of ASHP’s Pediatric Section Advisory Group as they discuss CHD, the care of children and adults with CHD, the role of pharmacists in the care of patients with CHD, and general clinical pearls for caring for these patients.

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Front-line informatics pharmacists and health-system IT leaders share COVID-19 Emergency Use Authorization treatments and vaccines informatics pearls. Topics discussed will include standard IT and operational procedures for EUAs, EHR and infusion pump builds, compliance and documentation, and their tips on preparing for the next wave of EUAs.   

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In this ASHP podcast, student members discuss ASHP’s Experiential Education program and dive into the ins and outs of an APPE rotation in association management. ASHP Pharmacy Student Forum Advisory Group members Rachael Crusius and Zach Krauss, engage with past ASHP externs about their virtual or in-person experiences and talk about how this rotation helped them to grow both professionally and personally in their pharmacy journey. 

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

The COVID-19 pandemic has caused changes in all practice settings of healthcare. The ambulatory setting has experienced some of the largest practice changes and advances. In this episode, we will explore how two ambulatory pharmacy leaders have navigated practice changes during this pandemic. 

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.